Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy
- 7 March 2024
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116302
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- SIRT7 in the aging processCellular and Molecular Life Sciences, 2022
- The role of SIRT2 in cancer: A novel therapeutic targetInternational Journal of Cancer, 2020
- Discovery of gamma-mangostin from Garcinia mangostana as a potent and selective natural SIRT2 inhibitorBioorganic Chemistry, 2020
- New SIRT2 inhibitors: Histidine-based bleomycin spin-offBioorganic & Medicinal Chemistry, 2019
- Sirtuins and Their Roles in Brain Aging and Neurodegenerative DisordersNeurochemical Research, 2016
- Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine–pyridine–histidine systemBioorganic & Medicinal Chemistry, 2015
- Synthesis and biological evaluation of l-cysteine derivatives as mitotic kinesin Eg5 inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- 2‐Anilinobenzamides as SIRT InhibitorsChemMedChem, 2006
- Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 geneBiochemical and Biophysical Research Communications, 2003
- Phylogenetic Classification of Prokaryotic and Eukaryotic Sir2-like ProteinsBiochemical and Biophysical Research Communications, 2000